Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies

被引：0
作者：
Aejaz Nasir
Timothy R. Holzer
Mia Chen
Michael Z. Man
Andrew E. Schade
机构：
[1] Eli Lilly and Company,Diagnostic and Experimental Pathology
[2] Eli Lilly and Company,Oncology Statistics
[3] Eli Lilly and Company,undefined
[4] Lilly Corporate Center,undefined
来源：
Cancer Cell International | / 17卷
关键词：
Breast cancer; HER2; Angiogenesis; VEGFR2; Ramucirumab; Antiangiogenic therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [42] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Yihong Wang
    Kamaljeet Singh
    Don Dizon
    Teresa Graves
    Ali Amin
    Evgeny Yakirevich
    Breast Cancer Research and Treatment, 2021, 186 : 667 - 676
  • [43] HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value
    Seo, An Na
    Kwak, Yoonjin
    Kim, Woo Ho
    Kim, Duck-Woo
    Kang, Sung-Bum
    Choe, Gheeyoung
    Lee, Hye Seung
    VIRCHOWS ARCHIV, 2015, 466 (06) : 645 - 654
  • [44] HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value
    An Na Seo
    Yoonjin Kwak
    Woo Ho Kim
    Duck-Woo Kim
    Sung-Bum Kang
    Gheeyoung Choe
    Hye Seung Lee
    Virchows Archiv, 2015, 466 : 645 - 654
  • [45] Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer
    Falchook, G. S.
    Moulder, S. L.
    Wheler, J. J.
    Jiang, Y.
    Bastida, C. C.
    Kurzrock, R.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 3004 - 3011
  • [46] Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer
    Maryam Ahmadzadeh
    Elham Mohit
    Biotechnology Letters, 2023, 45 : 371 - 385
  • [47] Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
    Atallah, Nehal M.
    Haque, Maria
    Quinn, Cecily
    Toss, Michael S.
    Makhlouf, Shorouk
    Ibrahim, Asmaa
    Green, Andrew R.
    Alsaleem, Mansour
    Rutland, Catrin S.
    Allegrucci, Cinzia
    Mongan, Nigel P.
    Rakha, Emad
    EUROPEAN JOURNAL OF CANCER, 2023, 195
  • [48] High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
    Nuciforo, Paolo
    Thyparambil, Sheeno
    Aura, Claudia
    Garrido-Castro, Ana
    Vilaro, Marta
    Peg, Vicente
    Jimenez, Jose
    Vicario, Rocio
    Cecchi, Fabiola
    Hoos, William
    Burrows, Jon
    Hembrough, Todd
    Ferreres, Juan Carles
    Perez-Garcia, Jose
    Arribas, Joaquin
    Cortes, Javier
    Scaltriti, Maurizio
    MOLECULAR ONCOLOGY, 2016, 10 (01) : 138 - 147
  • [49] Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach
    Balogun, Toheeb Adewale
    Iqbal, Muhammad Nasir
    Saibu, Oluwatosin Abideen
    Akintubosun, Michael Olawale
    Lateef, Olubodun Michael
    Nneka, Uche Catherine
    Abdullateef, Olayemi Taye
    Omoboyowa, Damilola Alex
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (23) : 12772 - 12784
  • [50] Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer
    Ahmadzadeh, Maryam
    Mohit, Elham
    BIOTECHNOLOGY LETTERS, 2023, 45 (03) : 371 - 385
12345